Beta Drugs Ltd Q2 FY26: Oncology Overachiever or Pharmaceutical Phenom?
(Revenues ₹204 Cr, PAT ₹24 Cr, ROCE 27%, and the only company making oncologists smile and auditors confused at the same time)
1. At a Glance
Beta Drugs Ltd is that rare small-cap stock where cancer drugs and compounding returns both spread aggressively. With a market cap of ₹1,756 crore, current price ₹1,740, and P/E of 38.8, it’s not your neighborhood penny pharma; it’s India’s oncology rocket pretending to be humble. The company just reported Q2 FY26 revenue of ₹204 crore, up 12.9% YoY, while PAT stood at ₹23.9 crore, slightly down 2.13% QoQ.
ROE and ROCE? A healthy 25.9% and 27%, respectively — like your blood reports saying “fit, just don’t stress.” Debt is at ₹146 crore, but with a debt-to-equity ratio of 0.66 and an interest coverage ratio of 6.03, even the lender seems relaxed. No dividends (again), but hey — who needs payouts when your sales grew 25.4% CAGR over 3 years?
So here’s the mood: The company’s oncology drugs are killing it (pun intended), while investors are busy calculating how many crores each molecule might add to the next quarter’s earnings.
2. Introduction
Imagine an Indian pharma company not hyped for Covid vaccines, but for cancer injections. Beta Drugs Ltd isn’t here to cure boredom in your portfolio; it’s here to remind you that oncology can be profitable too.
Founded by the Batra family, this company is quietly rewriting the oncology script — one cytotoxic vial at a time. Their client list reads like a who’s who of Indian pharma royalty: Glenmark, Torrent, Reliance Lifesciences, Cadila, and half of India’s chemists who probably spell “cytotoxic” incorrectly.
Beta Drugs’ growth is like a Bollywood comeback — not overnight, but with conviction. Over the last five years, profit grew at 37% CAGR, and sales grew at 32% CAGR, powered by its mix of contract manufacturing, own brands, exports, and APIs. The company calls its FY26 goal “₹450 crore topline.” Translation? We’re not Sun Pharma yet, but we’re coming for your lunch.
The market, however, isn’t entirely forgiving. With a P/B of 7.95, investors are paying top rupee for those cancer syringes. But let’s be real — in an industry where one new molecule can make you rich and another can wipe you out, Beta Drugs seems to be compounding with precision, not luck.
3. Business Model – WTF Do They Even Do?
Beta Drugs is like that multi-talented cousin who does four things at once — and somehow does them all well.
CDMO (48% of FY24 revenue): They manufacture oncology formulations for over 50 clients, including 20+ pharma giants. Think of Beta as the backstage scientist — no fame, just fat contracts. This segment grew 46% in two years, thanks to new clients and capacity for lyophilized products (basically, freeze-dried chemo drugs).
Own Brand Business (29%): The company’s brands like Canrib, Adcilib, and Beedan are sold in top hospitals like HCG and Artemis. They added 7 new products in FY24 alone. This is the retail face of the empire — prescription-driven, hospital-heavy, and clinically precise.
International Business (16%): Beta’s passports have more stamps than a Bigg Boss contestant’s ego — 46 countries, 250+ product registrations, and 53 new ones in FY24. With Latin America and Africa expansion on the cards, it’s spreading faster than stock tips on Twitter.
API Business (7%): The brainy, molecule-level stuff. They make their own oncology APIs like Azacitidine and Abiraterone — and even filed 6 DMFs in Brazil last year.
They’ve also built India’s first cytotoxic suspension facility — meaning they can make liquid cancer formulations that other Asian or European players can’t. If this were cricket, they just bowled a googly at their global competitors.
